Valeo Pharma Announces the Canadian Launch of Onstryv® (Safinamide Tablets) for the Treatment of Parkinson’s Disease

Valeo Pharma Inc. (CSE:VPH) (“Valeo”), a Canadian specialty pharmaceutical company with a primary focus on Neurodegenerative Diseases and Oncology, today announced the launch of Onstryv® (safinamide tablets) for the treatment of patients suffering from Parkinson’s Disease in Canada. Valeo has the exclusive rights to commercialize Onstryv® in Canada under a license agreement signed with Zambon S.p.A.